Navigation Links
New stem cell research could aid in battle against bulging waistlines
Date:6/16/2011

Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston (UTHealth) could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell.

The scientists have developed a bold approach for targeting fat-generating stem cells that one day could aid in the delivery of drugs that slow the cells' ability to direct fat expansion. Because these cells are also used in regenerative medicine, this approach may have wide applications. The cells are termed adipose stem cells.

The researchers used small artificial proteins (peptides) in a mouse model to identify a marker on the surface of adipose stem cells. Markers are molecules specifically expressed on individual cell types. The scientists screened about 100 billion peptides before finding one that was specific for mouse and human adipose stem cells.

"This marker, called delta-decorin, is specifically expressed on the surface of adipose stem cells, which are responsible for the production of white adipose tissue," said Mikhail Kolonin, Ph.D., the study's senior author and assistant professor of molecular medicine at the UTHealth Medical School. "This is the first prospective marker to be discovered for this particular type of adult stem cell."

Alexes Daquinag, Ph.D., the study's first author and postdoctoral fellow at the UTHealth Medical School, said, "In obesity, you have an overgrowth of white adipose tissue. It is made of adipocytes (fat cells) and one way to stop obesity is to target the progenitor cells adipose stem cells."

Kolonin added, "The existing approaches to identify adipose stem cells are based on combinations of semi-specific markers and are unreliable. Now we are able to target these cells with a new peptide probe for the purpose of tracing them in the body or controlled elimination."

The researchers report that delta-decorin, a modification of a previously defined protein, interacts with another clinically important protein called resistin on the surface of adipose stem cells. "The decorin-resistin connection is particularly interesting because both decorin and resistin have been previously implicated in Type-2 diabetes and other inflammation-related disease," Kolonin said.

"The next step will involve preclinical tests to see if we can develop the identified peptide into compounds that target these adipose stem cells," Kolonin said. "By depleting the adipose tissue progenitors, we may be able to provide long-term control of white fat."

Kolonin believes this approach could complement an anti-obesity compound he developed at The University of Texas MD Anderson Cancer Center before joining the UTHealth faculty. The compound called "Adipotide" works by targeting the blood vessels in fat and is licensed to Ablaris Therapeutics, Inc.

"Helping people lose weight might also reduce their risk of cardiovascular diseases, certain types of cancer, Type 2 diabetes and other obesity-related diseases," said Kolonin. Previous studies in Kolonin's laboratory have demonstrated the role of adipose stem cells in cancer progression.


'/>"/>

Contact: Robert Cahill
Robert.Cahill@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert  

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New stem cell research could aid in battle against bulging waistlines
(Date:2/27/2017)... ... 2017 , ... Miro is the ultimate smart media center that offers a ... TV shows and much more apps for user exploration. Its innovative acoustic design with ... 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi connection ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... New Jersey ... rates, among all types and genders. And the need for advanced services is growing. ... and its top-rated cancer care program, in collaboration with their non-profit partners in their ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... 2017 , ... IndustryArchive.Org . is announcing a new way for B2B ... now only pay for B.A.N.T. quality sales leads based on the Sellers decision to ... new reality that B2B buyers are controlling the sales process via the Internet and ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017   Royal Philips (NYSE: ... leader in health technology, today announced 510(k) clearance ... to market its ElastQ Imaging capability, further expanding ... systems. ElastQ Imaging enables simultaneous imaging of tissue ... for the diagnosis of various liver conditions. With ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... RGN-137, GtreeBNT Co., Ltd., received a positive response ... clinical trial design for RGN-137 to treat epidermolysis ... gel that incorporates Thymosin beta 4 ("Tß4") as ...
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
Breaking Medicine Technology: